Literature DB >> 16251414

Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells.

Barbara G Molenkamp1, Ronald J C L M Vuylsteke, Paul A M van Leeuwen, Sybren Meijer, Wim Vos, Pepijn G J T B Wijnands, Rik J Scheper, Tanja D de Gruijl.   

Abstract

Mature and immature myeloid dendritic cells (DCs) are thought to differentially modulate T-cell responses in secondary lymphoid tissues. Although mature DCs are believed to induce T-cell activation under proinflammatory conditions, immature DCs are believed to maintain a state of T-cell tolerance under steady state conditions. However, little is known about the actual activation state of human DCs under these different conditions. Here, we compare the frequency and activation state of human DCs between matched skin and sentinel lymph node (SLN) samples, after intradermal administration of either granulocyte/macrophage colony-stimulating factor (GM-CSF) or saline, at the excision site of stage I primary melanoma. Although DCs remained immature (CD1a+CD83-) and mostly situated in the epidermis of the saline-injected skin (fully consistent with a quiescent steady state), mature (CD1a+CD83+) DC frequencies significantly increased in the GM-CSF-injected skin and correlated with the number of mature DCs in the SLN, indicative of increased DC migration. Interestingly, irrespective of GM-CSF or saline administration, all CD1a+ myeloid DCs in the SLN were phenotypically mature (ie, CD83+). These data are indicative of migration of small numbers of phenotypically mature DCs to lymph nodes under steady state conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16251414      PMCID: PMC1603792          DOI: 10.1016/S0002-9440(10)61217-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

1.  Characterization of human skin-derived CD1a-positive lymph cells.

Authors:  C U Brand; R E Hunger; N Yawalkar; H A Gerber; T Schaffner; L R Braathen
Journal:  Arch Dermatol Res       Date:  1999 Feb-Mar       Impact factor: 3.017

Review 2.  Dendritic cells as a tool to induce anergic and regulatory T cells.

Authors:  H Jonuleit; E Schmitt; K Steinbrink; A H Enk
Journal:  Trends Immunol       Date:  2001-07       Impact factor: 16.687

3.  Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells.

Authors:  M L Albert; M Jegathesan; R B Darnell
Journal:  Nat Immunol       Date:  2001-11       Impact factor: 25.606

4.  Dendritic cell function in sentinel nodes.

Authors:  Richard Essner; Masayuki Kojima
Journal:  Oncology (Williston Park)       Date:  2002-01       Impact factor: 2.990

5.  The morphology, immunophenotype and distribution of paracortical dendritic leucocytes in lymph nodes regional to cutaneous melanoma.

Authors:  A M Lana; D R Wen; A J Cochran
Journal:  Melanoma Res       Date:  2001-08       Impact factor: 3.599

6.  Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma.

Authors:  A H Enk; H Jonuleit; J Saloga; J Knop
Journal:  Int J Cancer       Date:  1997-11-04       Impact factor: 7.396

7.  Selective Modulation of Paracortical Dendritic Cells and T-Lymphocytes in Breast Cancer Sentinel Lymph Nodes.

Authors:  Rong Rong Huang; Duan-Ren Wen; Jin Guo; Armando E. Giuliano; Mai Nguyen; Regina Offodile; Stacey Stern; Roderick Turner; Alistair J. Cochran
Journal:  Breast J       Date:  2000-07       Impact factor: 2.431

8.  Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin.

Authors:  K Toriyama; D R Wen; E Paul; A J Cochran
Journal:  J Invest Dermatol       Date:  1993-03       Impact factor: 8.551

9.  Sentinel lymph node investigation in melanoma: detailed analysis of the yield from step sectioning and immunohistochemistry.

Authors:  H A Gietema; R J C L M Vuylsteke; I A de Jonge; P A M van Leeuwen; B G Molenkamp; J R M van der Sijp; S Meijer; P J van Diest
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

10.  Rapid stereology based quantitative immunohistochemistry of dendritic cells in lymph nodes: a methodological study.

Authors:  Y van Hensbergen; S A Luykx-de Bakker; D A Heideman; G A Meijer; H M Pinedo; P J van Diest
Journal:  Anal Cell Pathol       Date:  2001       Impact factor: 2.916

View more
  11 in total

Review 1.  IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.

Authors:  Alexandra Kirner; Andrea Mayer-Mokler; Carsten Reinhardt
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  3.0 T relaxation time measurements of human lymph nodes in adults with and without lymphatic insufficiency: Implications for magnetic resonance lymphatic imaging.

Authors:  Rachelle Crescenzi; Paula M Donahue; Vaughn G Braxton; Allison O Scott; Helen B Mahany; Sarah K Lants; Manus J Donahue
Journal:  NMR Biomed       Date:  2018-10-12       Impact factor: 4.044

Review 3.  CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.

Authors:  Basav N Hangalapura; Laura Timares; Dinja Oosterhoff; Rik J Scheper; David T Curiel; Tanja D de Gruijl
Journal:  J Gene Med       Date:  2012-06       Impact factor: 4.565

4.  In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity.

Authors:  Jurjen M Ruben; Hetty J Bontkes; Theresia M Westers; Erik Hooijberg; Gert J Ossenkoppele; Arjan A van de Loosdrecht; Tanja D de Gruijl
Journal:  Oncoimmunology       Date:  2014-07-03       Impact factor: 8.110

5.  Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3.

Authors:  Rieneke van de Ven; Jelle J Lindenberg; Dinja Oosterhoff; M Petrousjka van den Tol; Rodney A Rosalia; Miho Murakami; Maaike Everts; George L Scheffer; Rik J Scheper; Tanja D de Gruijl; David T Curiel
Journal:  J Immunother       Date:  2009 Nov-Dec       Impact factor: 4.456

6.  In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma.

Authors:  Bas D Koster; Tamarah D de Jong; Mari F C M van den Hout; Berbel J R Sluijter; Ronald J C L M Vuylsteke; Barbara G Molenkamp; Saskia Vosslamber; M Petrousjka van den Tol; Alfons J M van den Eertwegh; Tanja D de Gruijl
Journal:  Oncoimmunology       Date:  2019-12-26       Impact factor: 8.110

7.  Advanced ovarian cancer: Vaccination site draining lymph node as target of immuno-modulative adjuvants in autologous cancer vaccine.

Authors:  Eduardo Lasalvia-Prisco; Emilio Garcia-Giralt; Silvia Cucchi; Jesús Vázquez; Leonard Robinson; John Dalton
Journal:  Biologics       Date:  2007-06

8.  IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation.

Authors:  Jelle J Lindenberg; Dinja Oosterhoff; Claudia C Sombroek; Sinéad M Lougheed; Erik Hooijberg; Anita G M Stam; Saskia J A M Santegoets; Henk J Tijssen; Jan Buter; Herbert M Pinedo; Alfons J M van den Eertwegh; Rik J Scheper; Hans J P M Koenen; Rieneke van de Ven; Tanja D de Gruijl
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

Review 9.  Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines.

Authors:  Dieke van Dinther; Dorian A Stolk; Rieneke van de Ven; Yvette van Kooyk; Tanja D de Gruijl; Joke M M den Haan
Journal:  J Leukoc Biol       Date:  2017-07-20       Impact factor: 4.962

10.  A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.

Authors:  Arjan A van de Loosdrecht; Sandra van Wetering; Saskia J A M Santegoets; Satwinder Kaur Singh; Corien M Eeltink; Yvonne den Hartog; Malika Koppes; Jorn Kaspers; Gert J Ossenkoppele; Ada M Kruisbeek; Tanja D de Gruijl
Journal:  Cancer Immunol Immunother       Date:  2018-07-23       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.